Jill Lacy, MD

Professor of Medicine (Medical Oncology)

Clinical Interests

  • Hodgkin Disease
  • Lymphoma
  • Medical Oncology

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Medical Oncology: Subset Medical Oncology Faculty

Brain Tumor Program

Yale Cancer Center: Brain Tumor Program | Gastrointestinal Cancers Program | Sarcoma Program

Yale Medicine

Office of Cooperative Research

Board Certifications

  • Internal Medicine AB of Internal Medicine (1982)

  • Medical Oncology AB of Internal Medicine (1993)

Clinical Trials

Conditions Study Title
Other Digestive Organ, Pancreas, Stomach Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies
Esophagus, Other Digestive Organ, Stomach A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)
Pancreas Phase II Study to Evaluate Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
Pancreas Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Meta Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Pancreas An Open-label, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343), an Anti-mesothelin Antibody Drug Conjugate, in Pretreated Mesothelin-expressing Advanced Pancreatic Cancer
Liver, Other Digestive Organ A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy
Liver A Phase II Trial of Systemic Chemotherapy (Gemcitabine and Cisplatin) in Combination with Conventional Transarterial Chemoembolization (cTACE) in Patients with Advanced Intra-Hepatic Cholangiocarcinoma (ICC)
Pancreas Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Other Digestive Organ A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5- Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Colon, Esophagus, Liver, Other Digestive Organ, Pancreas, Rectum, Small Intestine, Stomach A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Colon TAS-102 and Oxaliplatin (TAS-OX) for Refractory Metastatic Colon Cancer
Breast - Female, Breast - Male, Lung, Pancreas, Phase I A Phase II Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Hodgkin's Lymphoma, Kaposi's sarcoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Lymphoid Leukemia, Melanoma, skin, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Anus, Bladder, Bones and Joints, Brain and Nervous System, Breast - Female, Breast - Male, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Esophagus, Liver, Other Digestive Organ, Pancreas, Stomach An Open-Label, Multicenter Phase Ib Study of The Safety and Tolerability of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab And/Or Other Treatments in Patients With Solid Tumors
Colon, Rectum A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
Other Digestive Organ, Stomach A Phase Ib/II Study of MEDI4736 in Combination With Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects With Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
Pancreas Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
Esophagus, Other Digestive Organ A Study of DKN-01 in Combination With Paclitaxel
Pancreas Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (POLO)
Rectum Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer

Edit this profile

Contact Info

Jill Lacy, MD
Patient Care Location
Smilow Cancer Hospital at Yale-New HavenYale New Haven Hospital
20 York Street, Ste North Pavilion 8

New Haven, CT 06510
View on map...
Mailing Address
PO Box 208028
New Haven, CT 06520-8028